(TheNewswire)
Winnipeg, May 27, 2024. Cytophage Technologies Ltd.( TSXV:CYTO ) (“ Cytophage ” or the “Company”), the only publicly traded phage companythat is focused on bacteriophage solutions for both animal health andhuman health, is pleased to announce thatit has strengthened its board of directors with the addition of JohnSnisarenko, a 30+ year veteran of, and seasonedC-Suite executive in, the pharmaceutical and biotech industries.
Chairman of the Cytophage board, Harold Wolkin, commented: ”Wecontinue to add depth to our board, and that is really a reflection ofthe ambition of our team and what we are looking to accomplish overthe coming months. John is a most welcome addition to our team, andhis multi-faceted experience with pharmaceuticals and biotech will beinvaluable in guiding Cytophage’s product commercializationefforts.”
During his 30+ years in pharmaceutical and biotech industries, JohnSnisarenko focused on ophthalmology and eye care. John’s most recentposition was Chief Commercial Officer for Oyster Point Pharma, wherehe led the launch planning, infrastructure building and commerciallaunch for Tyrvaya. Prior to Oyster Point, John served as Group VicePresident and Head of the Ophthalmics Franchise at Shire (now Takeda),where he led a large, multidisciplinary team in the commercializationof Xiidra. He also served as a member of the Shire CommercialLeadership Team. Previously, John was the VP & Franchise Headresponsible for the commercial activities within Genentech’sOphthalmology (Lucentis) and Rheumatology (Rituxan, Actemra)franchises for 10 years. All three medicines achieved over $1B insales in the U.S. marketplace.
John also held various positions of increasing responsibility atCIBA Vision / Novartis Pharma Canada. In his last 9 years there, heserved as VP and Business Unit Head for Novartis Ophthalmics, holdinggeneral management responsibilities for the Canadianbusiness.
John holds a B.Sc. in Biochemistry and an MBA in Marketing andInternational Business from McGill University in Montreal, Canada. Heis currently serving as an Independent Director, Board Member andAdvisor to many start-up and established companies in both Canada andthe United States.
“With the increasing threat of antimicrobial resistance(“AMR”) to global health, I am honoured to join the board of atrue pioneer in bacteriophage solutions such as Cytophage”,commented John Snisarenko on his appointment. “I am excited to bringmy 30+ years of commercialization experience to the Cytophage board,and as the inaugural chair of their Commercialization Committee, I amvery much looking forward to lending my skills to getting theirproducts into the marketplace.”
For further information pleasecontact:
Heather Medwick
Chief Operating Officer
heather@cytophage.com
431 388 8873
Cytophage Investor Alerts: https://cytophage.com/subscribe/
About Cytophage Technologies
Cytophage Technologies ( TSXV:CYTO ) is apioneering biotechnology company dedicated to bacteriophage research,product development and commercialization. Committed to addressing theglobal challenge of antibiotic resistance, Cytophage advancesinnovative products that harness the power of bacteriophages to combatbacterial infections affecting human health, animal health, and foodsecurity.
Cautionary Statement onForward-Looking Information
This news release contains “forward-lookinginformation” and “forward-looking statements” (collectively,“forward-looking statements”) within the meaning of the applicableCanadian securities legislation. All statements, other than statementsof historical fact, are forward-looking statements and are based onexpectations, estimates and projections as at the date of this newsrelease. Any statement that involves discussions with respect topredictions, expectations, beliefs, plans, projections, objectives,assumptions, future events or performance (often but not always usingphrases such as “expects”, or “does not expect”, “isexpected”, “anticipates” or “does not anticipate”,“plans”, “budget”, “scheduled”, “forecasts”,“estimates”, “believes” or “intends” or variations of suchwords and phrases or stating that certain actions, events or results“may” or “could”, “would”, “might” or “will” betaken to occur or be achieved) are not statements of historical factand may be forward-looking statements. Forward-looking statementsinvolve known and unknown risks, uncertainties and other factors whichmay cause the actual results, performance or achievements of Cytophageto be materially different from any future results, performance orachievements expressed or implied by the forward-looking statements.Factors that could cause actual results to differ materially fromthose anticipated in these forward-looking statements are
described under the caption “Risk Factors” inCytophage’s Filing Statement dated January 30, 2024, which isavailable for view on SEDAR+ at www.sedarplus.ca. These risks includebut are not limited to, the risks associated with the bacteriophageindustry, such as operational risks in development or capitalexpenditures, the uncertainty of extensive regulatory approvalrequirements, government regulations, protection of intellectualproperty, product liability and rapid technological advancements.Forward-looking statements contained herein are made as of the date ofthis press release, and Cytophage disclaims, other than as required bylaw, any obligation to update any forward-looking statements whetheras a result of new information, results, future events, circumstances,or if management’s estimates or opinions should change, orotherwise. There can be no assurance that forward-looking statementswill prove to be accurate, as actual results and future events coulddiffer materially from those anticipated in such statements.Accordingly, the reader is cautioned not to place undue reliance onforward-looking statements.
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease.
Copyright (c) 2024 TheNewswire - All rights reserved.